- Home
- PLX vs VYGR Comparison
PLX vs VYGR Comparison
Compare PLX & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- VYGR
- Stock Information
- Founded
- PLX 1993
- VYGR 2013
- Country
- PLX United States
- VYGR United States
- Employees
- PLX N/A
- VYGR N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- PLX Health Care
- VYGR Health Care
- Exchange
- PLX Nasdaq
- VYGR Nasdaq
- Market Cap
- PLX 160.2M
- VYGR 165.5M
- IPO Year
- PLX 1998
- VYGR 2015
- Fundamental
- Price
- PLX $1.55
- VYGR $2.74
- Analyst Decision
- PLX Strong Buy
- VYGR Strong Buy
- Analyst Count
- PLX 1
- VYGR 8
- Target Price
- PLX $15.00
- VYGR $14.33
- AVG Volume (30 Days)
- PLX 1.4M
- VYGR 377.3K
- Earning Date
- PLX 05-09-2025
- VYGR 05-06-2025
- Dividend Yield
- PLX N/A
- VYGR N/A
- EPS Growth
- PLX N/A
- VYGR N/A
- EPS
- PLX 0.05
- VYGR N/A
- Revenue
- PLX $59,764,000.00
- VYGR $66,958,000.00
- Revenue This Year
- PLX $65.02
- VYGR N/A
- Revenue Next Year
- PLX $57.34
- VYGR $45.34
- P/E Ratio
- PLX $32.18
- VYGR N/A
- Revenue Growth
- PLX 0.18
- VYGR N/A
- 52 Week Low
- PLX $0.82
- VYGR $2.65
- 52 Week High
- PLX $3.10
- VYGR $9.55
- Technical
- Relative Strength Index (RSI)
- PLX 30.03
- VYGR 33.88
- Support Level
- PLX $1.54
- VYGR $2.71
- Resistance Level
- PLX $1.79
- VYGR $2.99
- Average True Range (ATR)
- PLX 0.11
- VYGR 0.18
- MACD
- PLX -0.02
- VYGR -0.05
- Stochastic Oscillator
- PLX 27.27
- VYGR 10.86
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.